FDA Formally Investigates Cancer Risk From Both Novartis SMA Gene Therapies After GLI1 Oncogene Activation Confirmed in Zolgensma Cases
· techtimes.com · popularity 20/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
FDA formally investigates Zolgensma cancer risk after confirming GLI1 oncogene activation; Itvisma also added to cancer probe despite zero reported tumors.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 6.